Publication | Closed Access

Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia

Tumor BiologyMalignant Pleural MesotheliomaReactive Mesothelial HyperplasiaMalignant DiseaseMedicinePathologyCancer BiologyCell BiologyMtap LossCancer Research